Related references
Note: Only part of the references are listed.Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
B. Fox et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
Michael R. Migden et al.
LANCET ONCOLOGY (2020)
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
Aleksi Suo et al.
ONCOLOGIST (2020)
Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma
Simon A. Mueller et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma
Alec J. Kacew et al.
EUROPEAN JOURNAL OF CANCER (2019)
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Elena Verzoni et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
A. Elkrief et al.
ANNALS OF ONCOLOGY (2019)
Management of Skin Cancer in the Elderly
Michael Renzi et al.
DERMATOLOGIC CLINICS (2019)
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer
Giulia Galli et al.
LUNG CANCER (2019)
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer
Mathieu Grangeon et al.
CLINICAL LUNG CANCER (2019)
Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
Alice Indini et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Ziming Wang et al.
NATURE MEDICINE (2019)
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L. Derosa et al.
ANNALS OF ONCOLOGY (2018)
Checkpoint blockade after kidney transplantation
Mathieu Lesouhaitier et al.
EUROPEAN JOURNAL OF CANCER (2018)
Age and immunity: What is immunosenescence?
Graham Pawelec
EXPERIMENTAL GERONTOLOGY (2018)
An ecological study of skin biopsies and skin cancer treatment procedures in the United States Medicare population, 2000 to 2015
David M. Wang et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas
Won Jin Ho et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation
Alma Aslan et al.
LEUKEMIA & LYMPHOMA (2017)
Immune checkpoint inhibitors and elderly people: A review
Amaury Daste et al.
EUROPEAN JOURNAL OF CANCER (2017)
Cancer Immunotherapies: Are They as Effective in the Elderly?
Kate Poropatich et al.
DRUGS & AGING (2017)
Validation of OncoPanel A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer
Elizabeth P. Garcia et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Comparing comorbidity scales: Attending physician score versus the Cumulative Illness Rating Scale for Geriatrics
Lene Kirkhus et al.
JOURNAL OF GERIATRIC ONCOLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
f Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M. Sholl et al.
JCI INSIGHT (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma
Curtis R. Pickering et al.
CLINICAL CANCER RESEARCH (2014)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Treatment tolerance and efficacy in geriatric oncology: A systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups
Ambuj Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier?
KWL Yee et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comorbidity and karnofksy performance score are independent prognostic factors in Stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies
S Firat et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Measuring comorbidity in older cancer patients
M Extermann
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
